Cerevel Therapeutics Holdings, Inc. (CERE) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Cambridge, MA, United States. El CEO actual es Ronald C. Renaud Jr.,.
CERE tiene fecha de IPO 2020-07-30, 355 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $8.19B.
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience diseases including schizophrenia, epilepsy, Parkinson's disease, and psychiatric disorders. The company's pipeline includes several lead programs in clinical development, such as emraclidine for schizophrenia, Darigabat for drug-resistant epilepsy and anxiety, and Tavapadon for Parkinson's disease, alongside multiple earlier-stage candidates targeting conditions like dementia-related apathy, substance use disorder, and major depressive disorder. Founded in 2018 and headquartered in Cambridge, Massachusetts, Cerevel leverages multiple molecular mechanisms and receptor targets to address critical unmet needs in central nervous system disorders.
